ImmunityBio, Inc.
IBRXBiotechnology
$8.29−5.15%As of Oct 30vs prior close
- Market cap
- $8.8B
- P/E (TTM)
- –
- From 52W high
- −28.23%
- EPS (LTM)
- -$0.97
- Revenue (LTM)
- $165.8M
- Net margin
- -598.56%
- Dividend yield
- 0.00%
Nomior Score
63
Ascendant MoverSpeculativeTop 20% of the scored universe
Growth78
Quality45
Value53
Momentum84
Resilience32
Growth
+139.32%revenue a year over 9 fiscal years
FY16 $44KLTM $165.8M
Connections
Revenue to profitQ2 FY26
The operating loss was 120% of revenue, narrower by 149 pts on a year.
Who owns it
2funds